{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:31:56Z","timestamp":1781883116528,"version":"3.54.5"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In this work, we evaluate the neutralizing activity of the following HIV-1 bNAbs: VCR07-523, N6, PGDM1400, CAP256-VRC26.25, 10-1074, PGT128, 10E8, and DH511.11P, which are directed to different Env surface epitopes. We used the global panel of HIV-1 pseudoviruses to analyze the bNAbs\u2019 potency and chose the most potent ones. To achieve maximum neutralization breadth and minimum IC50 concentration, the most effective antibodies were tested in double and triple combinations. Among the doubles, the combinations of N6+PGDM1400 and N6+PGT128 with IC50 \u2264 0.3 \u00b5g\/mL proved to be the most effective. The most effective triple combination was N6+PGDM1400+PGT128. Our data demonstrate that this combination neutralizes pseudoviruses of the global HIV-1 panel with IC50 \u2264 0.11 \u00b5g\/mL and IC80 \u2264 0.25 \u00b5g\/mL.<\/jats:p>","DOI":"10.3390\/v14091910","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T02:09:36Z","timestamp":1661911776000},"page":"1910","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-7813","authenticated-orcid":false,"given":"Evgeniya A.","family":"Kochina","sequence":"first","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, Moscow 119992, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2304-7787","authenticated-orcid":false,"given":"Felix A.","family":"Urusov","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, Moscow 119992, Russia"},{"name":"Izmerov Research Institute of Occupational Health, Moscow 105275, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem A.","family":"Kruglov","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, Moscow 119992, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina V.","family":"Glazkova","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, Moscow 119992, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German A.","family":"Shipulin","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, Moscow 119992, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Bogoslovskaya","sequence":"additional","affiliation":[{"name":"Centre for Strategic Planning and Management of Biomedical Health Risks, Federal Medical Biological Agency, Moscow 119992, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"ref_1","unstructured":"UNAIDS (2022, April 25). AIDS Statistics. Available online: https:\/\/www.unaids.org\/ru\/resources\/fact-sheet."},{"key":"ref_2","unstructured":"(2022, April 25). WHO. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drugresistance."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/imr.12513","article-title":"Genetic and structural analyses of affinity maturation in the humoral response to HIV-1","volume":"275","author":"Kepler","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Derking, R., Ozorowski, G., Sliepen, K., Yasmeen, A., Cupo, A., Torres, J.L., Julien, J.-P., Lee, J.H., van Montfort, T., and de Taeye, S.W. (2015). Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004767"},{"key":"ref_9","first-page":"81","article-title":"Broadly neutralizing antibodies for the treatment of HIV infection","volume":"13","author":"Glazkova","year":"2021","journal-title":"HIV Infect. Immunosuppr. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nprot.2017.126","article-title":"Transient expression of human antibodies in mammalian cells","volume":"13","author":"Nevoltris","year":"2018","journal-title":"Nat. Protoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies","volume":"88","author":"Hraber","year":"2014","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1134\/S0026893318020085","article-title":"Protection of Lymphocytes Against HIV using Lentivirus Vector Carrying a Combination of TRIM5\u03b1-HRH Genes and microRNA Against CCR5","volume":"52","author":"Omelchenko","year":"2018","journal-title":"Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Bailer","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV Neutralization in a Luciferase Reporter Gene Assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"Bhiman","year":"2016","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eaal2200","DOI":"10.1126\/sciimmunol.aal2200","article-title":"Potent and broad HIV-neutralizing antibodies in memory B cells and plasma","volume":"2","author":"Williams","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1523-5394.1998.006003195.x","article-title":"Rituximab: A New Therapeutic Monoclonal Antibody for Non-Hodgkin\u2019s Lymphoma","volume":"6","author":"Scott","year":"1998","journal-title":"Cancer Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1038\/ncomms9443","article-title":"Dose\u2013response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies","volume":"6","author":"Webb","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","article-title":"HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure","volume":"48","author":"Kwong","year":"2018","journal-title":"Immunity"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.chom.2020.03.018","article-title":"Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?","volume":"27","author":"Klasse","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1128\/JVI.01762-08","article-title":"Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C","volume":"82","author":"Binley","year":"2008","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"710044","DOI":"10.3389\/fimmu.2021.710044","article-title":"Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?","volume":"12","author":"Hsu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00991-17","DOI":"10.1128\/JVI.00991-17","article-title":"Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments","volume":"91","author":"Hraber","year":"2017","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41467-019-08658-4","article-title":"Improvement of antibody functionality by structure-guided paratope engraftment","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12977-019-0493-y","article-title":"Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1","volume":"16","author":"Moshoette","year":"2019","journal-title":"Retrovirology"},{"key":"ref_33","first-page":"9","article-title":"A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch","volume":"21","author":"Wang","year":"2020","journal-title":"eLife"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/9\/1910\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:19:53Z","timestamp":1760141993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/9\/1910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["v14091910"],"URL":"https:\/\/doi.org\/10.3390\/v14091910","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}